CClinicalTrials.gg
CompletedNCT04020939Updated Mar 17, 2021

The Role of Indocyanine Green Angiography Fluorescence on Intestinal Resections in Pediatric Surgery.

An interventional study of SPY imaging and Indocyanine Green in Intestinal Atresia, Necrotizing Enterocolitis and Hirschsprung Disease, sponsored by St. Justine's Hospital. Completed at 1 site in Canada. Open to participants aged 0 Years to 16 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-17.

Sponsored by St. Justine's Hospital · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
0 Years to 16 Years
Sex
All
01

Study summary

Background: Intestinal resections are commonly performed in the pediatric population. Perfusion of the bowel is one of the most important factors determining the viability of an intestinal anastomosis. Up to date, no ideal method to assess intestinal perfusion has proven its superiority.

Objectives:

Primary: The aim of this study is to establish the feasibility and impact of the use of indocyanine green technology on intestinal resection margins during elective and emergency pediatric surgeries.

Secondary: The secondary outcomes of interest include collection of adverse events and difficulties encountered with the use of the indocyanine green (ICG) technology. Postoperative surgical complications will also be recorded.

Study Design: An open observational clinical study will be performed by using a clinical drug (indocyanine green) and medical device (SPY Fluorescence Imaging) to assess intraoperatively intestinal perfusion in a specific pediatric population.

02

Conditions studied

  • Intestinal Atresia
  • Necrotizing Enterocolitis
  • Hirschsprung Disease
  • Gastroschisis
  • Intestinal Obstruction
  • Incarcerated Hernia
  • Intussusception
  • Malrotation
  • Volvulus
  • Meconium Ileus
  • Intestinal Perforation
  • Trauma

Keywords

  • SPY imaging
  • indocyanine green
  • pediatric surgery
  • ICG
  • intestinal resections
  • intestinal perfusion
03

Who can participate

Ages eligible
0 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Patients \< 16 years old
  • Admitted between September 2019 and September 2020
  • Patients undergoing a surgery at CHUSJ
  • Any diagnosis requiring intra-abdominal intestinal resection (including stoma reversal)
  • Written informed consent form from the parents or legal guardian

Exclusion criteria

Exclusion Criteria:

  • Patients > 16 years old
  • Patients with known allergy or sensitivity to iodine
  • Patients with known kidney or liver failure
  • Patients with known severe cardiac or pulmonary diseases
  • Informed consent unobtained or impossible due to refusal of parents, language barrier, or diminished comprehension
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Patients undergoing intestinal resections

    * Interventions to be administered: indocyanine green intravenous injection and subsequent visualisation of intestinal viability under fluorescence * Drug: Indocyanine green dye (ICG) Dosage: 0.5 mg/kg (diluted with aqueous solution) Maximum: 2 mg/kg Frequency: maximum of 3 boluses Duration: intraoperative use only

    Device: SPY imaging · Drug: Indocyanine Green

Interventions

  • DeviceSPY imaging

    Use of the SPY Pinpoint imaging device to evaluate intraoperative intestinal perfusion in children.

    Also known as: SPY PinPoint

  • DrugIndocyanine Green

    Intravenous injection of indocyanine green to evaluate the intestinal perfusion.

    Also known as: ICG, IC-Green

05

What researchers measure

Primary outcomes

  1. SPY System utility in intestinal resections in Pediatric Surgery

    To demonstrate the utility of intra-operative evaluation of intestinal viability using the SPY Fluorescence Imaging System to optimize the location of the resection margins in pediatric surgeries necessitating intestinal resections. - Rate of intestinal resection margins modifications by using the SPY technology

    Time frame: 1 year

Secondary outcomes

  1. Surgical complications

    * Number of anastomotic leaks * Number of strictures * Number of bowel obstructions

    Time frame: 1 year

  2. Length of stay

    In days

    Time frame: 1 year

  3. Operative time

    In minutes

    Time frame: 30 days

  4. Estimated blood losses

    In ml

    Time frame: 30 days

  5. Need for additional reoperations

    Number

    Time frame: 1 year

  6. Need for additional radiology interventions

    Number

    Time frame: 1 year

06

Study locations

1 site
  • CHU Sainte-Justine
    Montréal, Quebec H3T 1C5, Canada
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT04020939
Lead sponsor
St. Justine's Hospital
Responsible party
Nelson Piche (Pediatric Surgeon, St. Justine's Hospital) — Principal investigator
First posted
Jul 16, 2019
Start date
Mar 16, 2020
Primary completion
Mar 10, 2021
Completion
Mar 10, 2021
Last update
Mar 17, 2021

Study contacts

Nelson Piché, MD
principal investigator · St. Justine's Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion